"10.1371_journal.pone.0145842","plos one","2015-12-29T00:00:00Z","Catherine Schramm; Sandrine Katsahian; Katia Youssov; Jean-François Démonet; Pierre Krystkowiak; Frédéric Supiot; Christophe Verny; Laurent Cleret de Langavant; Anne-Catherine Bachoud-Lévi; European Huntington's Disease Initiative Study Group and the Multicentre Intracerebral Grafting in Huntington's Disease Group","INSERM U955 E01, Neuropsychologie interventionnelle, Institut Mondor de Recherche Biomédicale, Créteil, France; INSERM UMRS1138 E22, Science de l'information au service de la médecine personnalisée, Centre de Recherche des Cordeliers, Université Paris 5, Université Paris 6, Paris, France; Université Paris Est, Faculté de Médecine, Créteil, France; Ecole Normale Supérieure, Institut d’Etude de la Cognition, Paris, France; Assistance Publique-Hôpitaux de Paris, Service d’informatique et statistiques, Hôpital Européen Georges Pompidou, Paris, France; Assistance Publique-Hôpitaux de Paris, Centre National de Référence pour la Maladie de Huntington, Hôpital Henri Mondor, Créteil, France; Leenaards Memory Centre, Clinical Neurosciences Department, CHUV Lausanne, Lausanne, Switzerland; Centre Hospitalier Universitaire d'Amiens, Service de neurologie, Amiens, France; EA 4559 - Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP), Université de Picardie Jules Verne (UPJV), Amiens, France; SFR CAP-Santé (FED 4231), Amiens, France; Hôpital Erasme ULB, Service de Neurologie, Bruxelles, Belgium; CHU d'Angers, Centre de Référence des Maladies Neurogénétiques, Service de Neurologie, Angers, France","Conceived and designed the experiments: ACBL CS SK. Analyzed the data: CS SK. Wrote the paper: ACBL CS SK. Collected the data: ACBL KY JFD PK FS CV LCL.","CS was successively supported by the NeuroStemcell Consortium (European Community Seventh Framework Program grant agreement no. 222943) and by “Investments for the future” (ANR11INBS0011 NeurATRIS: Infrastructure de recherche translationnelle pour les biothérapies en Neurosciences). SK: no financial disclosures. KY: no financial disclosures. JFD has received financial support from Eli Lilly, Lundbeck, Novartis, Schwabe and Vifor Pharma over the Rebuttal letter past 2 years as a member of scientific boards and speaker at sponsored sessions. This financial support was completely unrelated to the work reported here. PK: no financial disclosures. FS: no financial disclosures. CV: no financial disclosures. LCL: no financial disclosures. CBL acted as a consultant for Teva, once, in 2014. She received grants from the Ministry of Health supporting the National Reference Center for Huntington’s Disease and several grants for academic trials provided by the Direction de la Recherche Clinique (APHP). She is a partner in several investments for the future projects (Labex IEC, Neuratris) and in an EU FP7 project (RepairHD). This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.",NA,NA,NA,"2015","12","Catherine Schramm","CS",10,TRUE,3,NA,2,3,TRUE,TRUE,TRUE,1,"10",TRUE
